# IRAKLIA (NCT05405166)

> SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05405166
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sanofi
- Conditions: Plasma Cell Myeloma Recurrent
- Interventions: Isatuximab IV; Isatuximab SC; Dexamethasone; Pomalidomide; Dexamethasone; Montelukast; Paracetamol / Acetaminophen; Diphenhydramine; Methylprednisolone
- Enrollment: 531
- Primary outcome: Overall Response Rate (ORR)
- Primary outcome: Observed Concentration Before Dosing (Ctrough) of Isatuximab at Steady State

## Commentary we found

- YouTube: 29
- X threads: 18
- Podcasts: 12

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=iraklia-nct05405166

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05405166", "email": "<work email>"}; the inbox owner confirms by the emailed link.